.png)
.png)
Head of Quantitative Pharmacology, Clinical Pharmacology
Adagio Therapeutics
Disclosure(s): Adagio Therapeutics: Employee, Stocks/Bonds; Institute for Clinical Pharmacodynamics: President
Dr. Ambrose is President of the Institute for Clinical Pharmacodynamics and has worked in the anti-infective drug development area for nearly 25 years at large pharmaceutical companies, contract research organizations and small research institutes. During this time, Dr. Ambrose has been involved with analyses and data generation for over 150 agents, spanning from small molecule (antibiotics and antifungal) to large molecule (monoclonal antibodies) antimicrobial agents. Dr. Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained through the use of non-clinical (in vitro and animal) PK-PD infection models have be leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities. Dr. Ambrose has been at the forefront using this approach for identifying effective anti-infective dosing regimens, regulatory decision-making and as support for FDA, EUCAST, CLSI, and USCAST susceptibility breakpoint determinations.
Dr. Ambrose is the author or coauthor of over 170 peer-reviewed scientific publications and approximately 300 scientific abstracts, and he has served as an Editor for four textbooks, most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice and served as Editor of Antimicrobial Agents and Chemotherapy. Because of his scientific contributions, Dr. Ambrose was awarded the 2021 Antimicrobial Agents Lecture (formally The ICAAC Lecture) ― a lifetime achievement award of the American Society of Microbiology.